| Old Articles: <Older 1021-1030 Newer> |
|---|
 |
Bio-IT World
February 18, 2004 |
Proteomics Goes Cellular Tissue microarrays save big on sample material and reagents. But more importantly, this new high-throughput technology is helping save the lives of cancer patients   |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
Bio-IT World
February 18, 2004 |
Smokin' Supercomputing Paracel's Jason Molle on solving the IT challenges of biological analysis |
Bio-IT World
February 18, 2004 |
A Guide to GeneMatcher Paracel's vice president of product management Joseph Borkowski explains the history and attributes of GeneMatcher, the company's massively parallel supercomputer designed to enhance bioinformatics algorithms, to editor-in-chief Kevin Davies. |
Bio-IT World
February 18, 2004 |
On the Up and Up Market values for biotec companies increase as they deal and deliver in the fourth quarter |
The Motley Fool
February 18, 2004
Jeff Hwang |
Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule. |
The Motley Fool
February 17, 2004
David Nierengarten |
Antisense Making Sense? An update on Genasense, its future, and how the antisense marketplace is shaping up. The FDA has agreed to review the new drug applications. |
The Motley Fool
February 12, 2004
Alyce Lomax |
Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack. |
Fast Company
February 2004
Bill Breen |
Dr. Dope's Connection David Watson, the CEO of the Dutch pharmaceutical R&D company Hortapharm, has assembled what is arguably the world's most comprehensive cannabis-seed library. |
Fast Company
February 2004
Bill Breen |
Pipe Dream? Rick Doblin has a prescription for fixing NIDA's ailing medical-marijuana program: establish an alternative. |
| <Older 1021-1030 Newer> Return to current articles. |
